UNSPSC 51102833: Chlorcyclizine/hydrocortisone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102833 Chlorcyclizine/hydrocortisone is a Commodity code that in recent state and local procurement shows minimal alignment with its nominal pharmaceutical active-ingredient scope. The recent opportunities tagged to this code cover naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, direct-to-manufacturer prescription programs, and medical and first aid supplies for emergency response — none of which center on chlorcyclizine/hydrocortisone compounds specifically. Issuing bodies include county health departments (Seminole County, Florida), state HHS commissions (Texas), municipal purchasing offices (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple state and local facilities including Oregon). The work being solicited under this code spans pharmaceutical procurement at scale, including annual supply contracts for emergency medications, competitive bidding for medical consumables used in fire and rescue operations, and vendor qualification for direct manufacturer relationships within pharmacy benefit programs.

Recent activity clusters in Florida, Texas, Minnesota, and Oregon. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: posted date is 2026 but response deadline reflects an earlier year, signaling a data quality issue in the source). The City of Tampa issued IFB 26-P-00145 on March 25, 2026, for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with a $700,000 estimated contract value and SLBE set-aside eligibility. Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs without identifying specific budget ranges. MMCAP posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across multiple state and local jurisdictions, with proposals due March 26, 2026, and awards effective July 1, 2026. This code shows little focused activity in its stated therapeutic category and appears to be a misalignment between the taxonomy label and actual state and local buying patterns for emergency response and broad pharmaceutical supply.